A double-blind, randomized, 26-week study comparing the cognitive and psychomotor effects and efficacy of 75 mg (37.5 mg b.i.d.) venlafaxine and 75 mg (25 mg mane, 50 mg nocte) dothiepin in elderly patients with moderate major depression being treated in general practice

Journal of Psychopharmacology

Volumn 18, Issue 2, 2004, Pages 205-214

  Trick, Leanne ^a   Stanley, Neil ^a   Rigney, Una ^a   Hindmarch, Ian ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Antidepressant; Cognitive function; Dothiepin; Efficacy; Elderly patients; Psychomotor performance; Venlafaxine

Indexed keywords

DOSULEPIN; VENLAFAXINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACCIDENT SCORING QUESTIONNAIRE; ADULT; AGED; ARTICLE; BACKACHE; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL FLICKER FUSION; DAILY LIFE ACTIVITY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENERAL PRACTICE; HAMILTON SCALE; HEADACHE; HUMAN; INFLUENZA; INSOMNIA; LEEDS SLEEP EVALUATION QUESTIONNAIRE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MILFORD EPWORTH SLEEPINESS SCALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOMOTOR PERFORMANCE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY TRACT INFECTION; SHORT FORM 36 QUESTIONNAIRE; SHORT TERM MEMORY; SLEEP DISORDER; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA;

AGED; COGNITION; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DISORDERS OF EXCESSIVE SOMNOLENCE; DIZZINESS; DOTHIEPIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLICKER FUSION; HUMANS; MALE; NARCOLEPSY; NAUSEA; PSYCHOMETRICS; PSYCHOMOTOR PERFORMANCE; TIME FACTORS;

EID: 3242664275     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881104042622     Document Type: Article

References (57)

1. Anderson I M (2001) Meta-analytical studies on new antidepressants. Br Med Bull 57: 161-178
2. Anderson I M, Tomenson B M (1994) The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 8: 238-249
3. Anderson I M, Tomenson B M (1995) Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic anti-depressants: a meta-analysis. Br Med J 310: 1433-1438
4. Augustin B G, Cold J A, Jann M W (1997) Venlafaxine and nefazadone, two pharmacologically distinct antidepressants. Pharmacotherapy 17: 511-530
5. Beaumont G, Baldwin D, Lader M (1996) A criticism of the practice of prescribing subtherapeutic doses of antidepressants for the treatment of depression. Hum Psychopharmacol 11: 283-291
6. Benedictis E (2000) Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol 14: 61-66
7. Brazier J E, Harper R, Jones N N B (1992) Validating the SF36 health survey questionnaire: new outcome measure for primary care. Br Med J 305: 160-164
8. Broadbent D E, Cooper P F, Fitzgerald P, Parkes K R (1982) The cognitive failures questionnaire and its correlates. Br J Clin Psychol 21: 1-16
9. Einarson T R, Arikian S R, Casciano J, Doyle J J (1999) Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Therapeut 21: 296-308
10. Entsuah A R (2000) Response and remission with venlafaxine, SSRIs, or placebo in subpopulations with major depression. Poster session presented at 10th AEP Congress, Prague
11. Fairweather D B, Dal Pozzo C, Kerr J S, Lafferty S V, Hindmarch I (1997) Citalopram compared to dothiepin and placebo: effects on cognitive function and psychomotor performance. Hum Psychopharmacol Clin Exp 12: 119-126
12. Fairweather D B, Stanley N, Yoon J S, Hindmarch I (1999) The effects of fluoxetine and dothiepin on cognitive function in depressed patients in general practice. Hum Psychopharmacol Clin Exp 14: 325-332
13. Frank E, Prien R F, Jarrett J B (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse and recurrence. Arch Gen Psychiatry 48: 796-800
14. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62
15. Hindmarch I (1975) A 1-4 benzodiazepine, temazepam (K3917), its effect on some psychological parameters of sleep and behaviour. Arzneim Forsch (Drug Research) 25: 1836-1839
16. Hindmarch I (1980) Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 10: 189-209
17. Hindmarch I (1981) Measuring the effect of psychoactive drugs on higher brain activity. In Burrows G, Werry J S (eds), Advances in human psychopharmacology, vol. 2. JAI Press, Connecticut
18. Hindmarch I (1982) Critical flicker fusion frequency (CFF): the effects of psychotropic compounds. Pharmacopsychiatria 15 (Suppl 1): 44-48
19. Hindmarch I (1997) Do we need new antidepressants? Hum Psychopharmacol Clin Exp 12: S115-S119
20. Hindmarch I (1999) The impact of psychotropic medication on daily activities: the behavioural toxicity of antidepressants. Primary Care Psychiatry 5: S17-S20
21. Hindmarch I (2001) Expanding the horizons of depression: beyond the monamine hypothesis. Hum Psychopharmacol Clin Exp 16: 203-218
22. Hindmarch I, Parrott A C (1979) The effects of repeated nocturnal doses of clobazam, dipotassium chlorazepate and placebo on subjective ratings of sleep and early morning behaviour and objective measures of arousal, psychomotor performance and anxiety. Br J Clin Pharmacol 8: 325-329
23. Hindmarch I, Parrott A C, Lanza M (1979) The effects of an ergot alkaloid derivative (hydergine) on aspects of psychomotor performance, arousal, and cognitive processing ability. J Clin Pharmacol 19: 726-732
24. Hunt S M, McKenna S P (1992) The QLDS: a scale for the measurement of quality of life in depression. Health Policy 22: 307-319
25. Jenkinson C, Coulter A, Wright L (1993) Short form 36 (SF 36) New England medical center health survey questionnaire: normative data for adults of working age. Br Med J 306: 1437-1440
26. Johns M W (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14: 540-545
27. Johns M W (1992) Reliability and factor analysis of the Epworth sleepiness scale. Sleep 15: 376-381
28. Kasper S, Heiden A (1995) Do SSRIs differ in their antidepressant efficacy. Hum Psychopharmacol Clin Exp 10: S163-S172
29. Kerr J S, Fairweather D B, Hindmarch I (1997) The effect of paroxetine and dothiepin on subjective sleep in depressed patients. Hum Psychopharmacol Clin Exp 12: 71-73
30. Khan A, Fabre L F, Rudolph R (1991) Venlafaxine in depressed outpatients. Psychopharmacol Bull 27: 141-144
31. Mehtonen O, Søgaard J, Roponen P, Behnke K (2000) Randomized, double-blind comparison of venlafaxine and setraline in outpatients with major depressive disorder. J Clin Psychiatry 61: 95-100
32. Mendels J, Johnston R, Mattes J, Reisenberg R (1993) Efficacy and safety of b.i.d doses of venlafaxine in a dose response study. Psychopharmacol Bull 29: 169-174
33. Montgomery S A, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389
34. Montgomery S A, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D (1994) Selective serotonin reuptake inhibitors: meta analysis of discontinuation rates. Int Clin Psychopharmacol 9: 47-53
35. Montgomery S A, Kasper S (1995) Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 9 (Suppl 4): 33-40
36. Muth E A, Haskins J T, Moyer J A, Husbands G E, Nielsen S T, Sigg S B (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35: 4493-4497
37. Norman T R (1993) Pharmacokinetic aspects of antidepressant treatment in the elderly. Progr Neuropsychopharmacol Biol Psychiatry 17: 329-344
38. O'Hanlon J F, Robbe H W, Vermeeren A, van Leeuwen C, Danjou P E (1998) Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol 18: 212-221
39. Paes De Sousa M, Figuiera M L, Loureiro F, Hindmarch, I (1981) Lorazepam and clobazam in anxious elderly patients. Royal Soc Med Int Congr Symp Ser 43: 119-123
40. Pande A C, Sayler M E (1993) Adverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol 8: 267-269
41. Parrott A C, Hindmarch I (1978) Factor analysis of a sleep evaluation questionnaire. Psychol Med 8: 325-329
42. Peretti S, Judge R, Hindmarch I (2000) Safety and tolerability considerations: tricyclic antidepressants versus selective serotonin reuptake inhibitors. Acta Psychiatr Scand 101 (Suppl 403): 17-25
43. Pinder R M (2001) On the feasibility of designing new antidepressants. Hum Psychopharmacol Clin Exp 16: 53-59
44. Poirier M F (1999) The concept of resistant depression and therapeutic strategies, particularly with venlafaxine. Encephale 25: 55-57
45. Poirier M F, Boyer P (1999) Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 175: 12-16
46. Preskorn S H (1993) Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 94 (Suppl 5A): 42-12
47. Prien R F, Carpenter L L, Kupfer D J (1991) The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry 48: 796-800
48. Rudolph R L, Feiger A D (1999) A double blind, randomised, placebo-controlled trial of once daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 50: 171-181
49. Schweiser E, Weise C, Clary C, Fox I, Rickels K (1991) Placebo controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 11: 233-236
50. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180: 396-404
51. Snow V, Lascher S, Mottur-Pilson C (2000) Pharmacologic treatment of acute major depression and dysthymia. Annal Int Med 132: 738-742
52. Thase M E, Entsuah A R, Rudolph R L (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178: 234-241
53. Trindade E, Menon D, Topfer L, Coloma C (1998) Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Can Med Assoc J 159: 1245-1252
54. Tylee A, Beaumont G, Bowden M W, Reynolds A (1997) A double-blind, randomized, 12 week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry 3: 51-58
55. Wade A, Despiegel N, Reines E (2002) Depression in primary care patients: improvement during long term escitalopram treatment. Fifteenth ECNP Congress, 5-9 October. Barcelona, Spain
56. Ware J, Snow W W, Kosinski M, Gandek B (1993) SF-36 health survey: manual and interpretation guide. The Health Institute, Boston, MA
57. Woodworth R, Schlosberg H (1958) Experimental psychology. Methuen, London